Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06223048 · ClinicalTrials.gov registry record · Phase 2
A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma
A Phase 2 study of Primary Open Angle Glaucoma, sponsored by Amydis.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 3
- Study locations
NCT06223048: Recruiting Phase 2 study of Primary Open Angle Glaucoma, sponsored by Amydis.
NCT06223048 is a Phase 2 study of Primary Open Angle Glaucoma that is actively recruiting participants, run by Amydis. The registered enrollment target is 50 participants, below the 292-participant average among 19 other Primary Open Angle Glaucoma trials with a reported enrollment target (83% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06223048, a Phase 2 study of Primary Open Angle Glaucoma, is actively recruiting participants, sponsored by Amydis.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this research study is to assess the ability of AMDX- 2011P to identify amyloid deposits in the retina of participants with Primary Open Angle Glaucoma (POAG).
Conditions Studied
Interventions
- DRUG AMDX-2011P
Study Locations (3)
California
- Global Research Management - Glendale
- Eye Research Foundation - Newport Beach
Arizona
- Associated Retina Consultants - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-12-07 |
| Est. Completion | 2025-02 |
| Phase | Phase 2 |
What NCT06223048 shows while recruiting
NCT06223048 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 292-participant average among 19 other Primary Open Angle Glaucoma trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Primary Open Angle Glaucoma appearing as the primary indexed condition, and to 1 intervention - of which AMDX-2011P is the first listed.
NCT06223048 reports a single indexed study location in California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06223048 about?
NCT06223048 is a clinical study titled "A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma". The purpose of this research study is to assess the ability of AMDX- 2011P to identify amyloid deposits in the retina of participants with Primary Open Angle Glaucoma (POAG).
What is the current status of trial NCT06223048?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2023-12-07. Estimated completion is 2025-02.
What conditions does trial NCT06223048 study?
This clinical trial studies the following conditions: Primary Open Angle Glaucoma.
What interventions are being tested in trial NCT06223048?
The interventions under investigation include: AMDX-2011P (DRUG).
Who is sponsoring clinical trial NCT06223048?
This trial is sponsored by Amydis, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06223048 being conducted?
This trial has 3 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Open Angle Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06223048's enrollment target sits among peer trials
50 18th of 19 higher than 2 of 19 other Primary Open Angle Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Primary Open Angle Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study
ACTIVE NOT RECRUITING · Phase 2
-
Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma
COMPLETED · Phase 2
-
Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma
COMPLETED · Phase 2
-
Ahmed Glaucoma Valve Surgery With Mitomycin-C
COMPLETED · Phase 2
-
Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).
COMPLETED · Phase 2
-
Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI